+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation



Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation



Blood 76(6): 1092-1097



T cells from allogeneic bone marrow grafts are responsible for a graft versus leukemia effect. Use of recombinant Interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT) may enhance immune function and hopefully reproduce the allogeneic reaction. We report here the hematologic and immunologic changes observed in the first 10 patients of a phase 1 trial studying the infusion of IL-2 after autologous BMT. All patients had high-risk malignancies and received 6 days of a constant infusion of IL-2 (Eurocetus, Amsterdam, The Netherlands) at dose of 3 x 10(6) Cetus Units/m2/d, 79 +/- 12 days after autologous BMT. Clinical toxicities involving cutaneous, cholestatic, gastrointestinal, and hemodynamic effects occurred during IL-2 treatment but reversed in all cases. Completion of treatment was 91% of the scheduled dose of IL-2. Hematologic toxicity was moderate and transient with no graft failure. Increases in eosinophil and lymphocyte counts were significant (P less than .05). Stimulation of the immune system was intense and prolonged, manifested by increase numbers of CD3+, CD3+DR+, CD3+ CD25+ lymphocytes, and natural killer (NK) cells (all P less than .01), and increase of Lymphokine-activated killers (LAK) and NK activities (P less than .01 and P less than .05). This study establishes the feasibility of a 6-day administration of rIL-2 after autologous BMT leading to a major immune activation 2.5 months after BMT.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040260847

Download citation: RISBibTeXText

PMID: 2400805


Related references

Systemic administration of recombinant interleukin 2 il2 after autologous bone marrow transplantation bmt a pilot study in 19 patients. Journal of Cellular Biochemistry Suppl. (14 Part B): 105, 1990

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79(2): 517-526, 1992

Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects. Journal of HematoTherapy 4(2): 113-120, 1995

Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 77(12): 2561-2568, 1991

Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 86(4): 1619-1628, 1995

Clinical and immunologic effects of continuous infusion interleukin 2 after allogeneic and autologous bone marrow transplantation. Clinical Research 39(2): 431A, 1991

Immunomodulatory effects of low dose interleukin-2 administration after autologous bone marrow transplantation. Bone Marrow Transplantation 12(Suppl. 3): S75, 1993

Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. Journal of Clinical Oncology 14(11): 3018-3025, 1996

Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Seminars in Oncology 20(6 Suppl 9): 41-45, 1993

Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Progress in Clinical and Biological Research 389: 229-238, 1994

Interleukin 3 for graft failure following autologous bone marrow transplantation for hematologic malignancies. Experimental Hematology (Charlottesville) 20(6): 772, 1992

Interleukin-2 as a consolidative treatment after autologous bone marrow transplantation for hematologic malignancies. Blood 86(10 Suppl. 1): 957A, 1995

Effects of in vivo administration of human recombinant IL-2 to cynomolgus monkeys after autologous bone marrow transplantation. Transplantation Proceedings 19(6 Suppl 7): 157-161, 1987

Immunologic effects of interleukin-12 therapy after autologous stem cell transplantation for hematologic malignancies. Blood 98(11 Part 1): 691a, 2001

Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematologica 89(Suppl. 1): 2-7, 1993